newsfilter
← Latest News
GlobeNewswire·

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for homocystinuria (HCU) and